Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Diabetes Discourse

Sodium-Glucose Transporters: A New Class of Diabetes Medications

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Comments
  • Overview

    SGLT2 is responsible for glucose re-absorption in the kidney and decreasing SGLT2 function promotes glucose excretion to help reduce blood sugar levels, making it an attractive area for the treatment of diabetes. Join host Dr. Steven Edelman and his guest, professor of medicine at Tulane University, Dr. Vivian Fonseca, as they discuss the new class of medications being investigated for the treatment of type-2 diabetes.

Recommended
Details
Presenters
Comments
  • Overview

    SGLT2 is responsible for glucose re-absorption in the kidney and decreasing SGLT2 function promotes glucose excretion to help reduce blood sugar levels, making it an attractive area for the treatment of diabetes. Join host Dr. Steven Edelman and his guest, professor of medicine at Tulane University, Dr. Vivian Fonseca, as they discuss the new class of medications being investigated for the treatment of type-2 diabetes.

Schedule31 Oct 2024